New and emerging therapies for pulmonary complications of cystic fibrosis

Drugs

Volumn 61, Issue 10, 2001, Pages 1379-1385

  Tonelli, Mark R ^a   Aitken, Moira L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ARYLBUTYRIC ACID DERIVATIVE; GENISTEIN; IBUPROFEN; PREDNISONE; TRANSMEMBRANE CONDUCTANCE REGULATOR; URIDINE TRIPHOSPHATE; XANTHINE DERIVATIVE;

BRONCHIECTASIS; CYSTIC FIBROSIS; DRUG EFFICACY; GENE THERAPY; HUMAN; REVIEW; SPIROMETRY;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; INFLAMMATION; LUNG DISEASES; PROGNOSIS; STEROIDS;

EID: 0034859709     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161100-00001     Document Type: Review

References (40)

1. Management of pulmonary disease in patients with cystic fibrosis
2. Cystic fibrosis
3. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
4. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
5. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis
6. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis
7. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
8. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation
9. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal surface fluid
10. Current understanding of the inflammatory process in cystic fibrosis
11. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection
12. Risks of alternate-day prednisone in patients with cystic fibrosis
13. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis
14. The use of anti-inflammatory medications in cystic fibrosis: Trends and physician attitudes
15. Inhaled corticosteroids for cystic fibrosis
16. Effect of high-dose ibuprofen in patients with cystic fibrosis
17. Transient renal failure due to simultaneous ibuprofen and aminoglycoside
18. Oral non-steroidal anti-inflammatory drag therapy for cystic fibrosis
19. Anti-inflammatory activity of macrolide antibiotics
20. Effects of long-term administration of erythromycin on cytokine production
21. Macrolide antibiotics for cystic fibrosis (Cochrane review)
22. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis
23. The Flutter VRP1 as an adjuct to chest physiotherapy in cystic fibrosis
24. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis
25. Effect of aerosolized recombinant DNase on exacerbations of respiratory symtoms and on pulmonary function in patients with cystic fibrosis
26. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I
27. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis
28. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis
29. Pharmacological treatment of the ion transport defect in cystic fibrosis
30. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial
31. Pharmacological modulation of ion transport across wild-type and DeltaF508
32. A pilot study of aerosolized amiloride for the treatment of lung disease
33. Gene therapy for lung disease: Hype or hope?
34. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
35. Administration of an adenovims containing the human CFTR CDNA to the respiratory tract of individuals with cystic fibrosis
36. A controlled study of adeonviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
37. Repeat administration of an adenovirus vector encoding cystic fibrosis
38. A placebo-controlled study of liposome-mediated gene transfer to the nasal
39. Repeat administration of DNA/liposomes to the nasal epithelium of patients